The BCR-ABL oncoprotein of chronic myeloid leukemia can be converted into an active killer of the malignant cell when allowed to enter the nucleus. Could this lead to a three-step strategy to improve molecular targeting in the treatment of leukemia (pages 228–234)?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RNA quantification using gold nanoprobes - application to cancer diagnostics
Journal of Nanobiotechnology Open Access 24 February 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nowell, P.C. & Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497–1497 (1960).
Deininger, M.W., Goldman, J.M. & Melo, J.V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343–3356 (2000).
Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100–104 (1996).
Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561–566 (1996).
Deininger, M.W.N., Goldman, J.M., Lydon, N.B. & Melo, J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 90, 3691–3698 (1997).
le Coutre, P. et al. In vivo eradication of human BCR/ABL positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91, 163–168 (1999).
Vigneri, P. & Wang, J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nature Med. 7, 228–234 (2001).
Wen, S.T., Jackson, P.K. & Van Etten, R.A. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 15, 1583–1595 (1996).
Taagepera, S. et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA 95, 7457–7462 (1998).
Lewis, J.M., Baskaran, R., Taagepera, S., Schwartz, M.A., & Wang, J.Y. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic- nuclear transport. Proc. Natl. Acad. Sci. USA 93, 15174–15179 (1996).
Van Etten, R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell. Biol. 9, 179–186 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melo, J. Inviting leukemic cells to waltz with the devil. Nat Med 7, 156–157 (2001). https://doi.org/10.1038/84591
Issue Date:
DOI: https://doi.org/10.1038/84591
This article is cited by
-
RNA quantification using gold nanoprobes - application to cancer diagnostics
Journal of Nanobiotechnology (2010)
-
Subcellular distribution of p210BCR-ABL in CML cell lines and primary CD34+ CML cells
Leukemia (2008)